UBT251 Injection Phase II Clinical Study (CKD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

Also called NCT07134335

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07134335
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07134335. Randomized; double masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2030-07-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
UBT251 Injection Phase II Clinical Study (CKD)
Condition
Obesity &Amp; Overweight
Intervention (Drug)
UBT251
Intervention (Drug)
UBT251
Intervention (Drug)
UBT251
Lead sponsor
The United Bio-Technology (Hengqin) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07134335
Content hash
f5c5d590052414428e63d33f447f1d1659c7115bcac47695172024abd0b38f46